#Vaccine Market Trends

[industryforecastnews]

Vaccine Market To Reach USD 110.54 Billion By 2030

Vaccine Market Growth & Trends

The global vaccine market size is expected to reach USD 110.54 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.74% from 2024 to 2030. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/vaccine-market

Vaccine Market Report Highlights

By type, the mRNA segment dominated the vaccine market with a share of 32.32% in 2023. However, the subunit vaccine segment is expected to grow at the fastest CAGR of 8.1% during the forecast period

By route of administration, the parenteral administration is anticipated to capture the majority of the vaccine market share throughout the forecast period. Parenteral administration reduces the risk of contamination compared to other routes of administration thus contributing to the segments’ dominance

By disease indication, the viral diseases segment captured the largest share of the vaccine market in 2023, majorly attributed to the high distribution of COVID-19 vaccines during 2021 and 2022

By age, pediatrics is expected to witness the fastest growth during the forecast period, as many countries have established national immunization programs that require children to receive certain shots as part of routine childhood vaccinations

By distribution channel, pharmacies are anticipated to be the fastest-growing segment. This growth can be attributed to the increased accessibility and convenience for patients, and the potential for increased revenue and profitability for pharmacies

North America region is expected to grow at the fastest CAGR during the forecast period. The region is dominated by a few key players, including Pfizer, Moderna, Sanofi Pasteur, and Merck. These companies have a strong presence in the market, with established distribution networks and significant investment in vaccine research and development

Vaccine Market Segmentation

Grand View Research has segmented the global vaccine market on the basis of type, route of administration, disease indication, age group, distribution channel, and region

Vaccine Type Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Subunit Vaccines

Recombinant vaccines

Conjugate Vaccines

Toxoid vaccines

Inactivated

Live Attenuated

mRNA vaccines

Viral vector vaccines

Vaccine Route Of Administration Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Oral

Parenteral

Nasal

Vaccine Disease Indication Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Viral Diseases

Hepatitis

Influenza

HPV

MMR

Rotavirus

Herpes Zoster

Covid-19

Others

Bacterial Vaccines

Meningococcal Diseases

Pneumococcal diseases

DPT

Others

Cancer Vaccines

Allergy Vaccines

Vaccine Age Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Pediatric

Adult

Vaccine Distribution Channel Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Hospital & Retail Pharmacies

Government Suppliers

Others

Vaccine Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the Vaccine Market

Serum Institute of India Pvt. Ltd.

Seqirus

Sanofi

GSK Plc.

Merck & Co., Inc.

Pfizer Inc.

Moderna Inc.

Sinovac

BioNTech SE

AstraZeneca

Browse Full report: https://www.grandviewresearch.com/industry-analysis/vaccine-market

[bishtmeenakshi]

Vaccinating the World: Can the Market Deliver on Its Promise?

Explore the potential of the vaccine market to deliver on its promise of global immunization. Analyze trends, size, and future outlook across various vaccine segments, including pneumococcal, dengue, DNA, typhoid fever, and foot and mouth disease vaccines market.

[shwetammr1]

Pentavalent Vaccine Market Industry Summary, Magnitude, Key Motivators, and Future Shifts

Pentavalent Vaccine Market size was valued at USD 2.64 Bn. in 2023 and the total revenue is expected to grow at a CAGR of 3.3% through 2024 to 2030, reaching nearly USD 3.31 Bn.

[colinwilson11]

Viral Vaccine Cell Culture Media Market Will Grow At Highest Pace Owing To Rising Prevalence Of Viral Infections

Viral vaccine cell culture media are essential growth mediums required for the propagation of viruses, used in the manufacturing of viral vaccines. It provides necessary nutrients to sustaining and propagation of cells outside of living organism. The composition of viral vaccine cell culture media varies depending on specific requirements and types of viruses being cultivated. It contains necessary salts, amino acids, proteins, vitamins and other organic compounds essential for growth of cells. The advantages associated with viral vaccine cell culture media include standardized and defined composition, ease of scale-up for large-scale manufacturing, and supporting growth of anchorage-dependent and suspension-adapted cells. The need for viral vaccine cell culture media is growing owing to rising incidences of viral infections and technological advancements in vaccine development.

The Viral Vaccine Cell Culture Media Market is estimated to be valued at US$ 1.8 Bn in 2024 and is expected to exhibit a CAGR of 5.8 % over the forecast period 2024-2031.

Key Takeaways

Key players operating in the viral vaccine cell culture media are Thermo Fisher Scientific, Merck, Sartorius,Creative Biolabs, Xell. Thermo Fisher Scientific dominates the market with wide range of viral vaccine cell culture media products.

Rising prevalence of viral infections such as influenza, COVID-19, hepatitis, and others is driving the demand for viral vaccines exponentially. As viral vaccines are manufactured using cell culture technologies, their growing demand is directly fueling the viral vaccine cell culture media market.

Advancements in cell culture technologies, serum-free and chemically defined media are helping overcome issues related to undefined compositions and lot-to-lot inconsistencies. These technologies are supporting more reproducible and scalable manufacturing of viral vaccines.

Market Trends

Serum-free and chemically defined media - These media eliminates risks of contamination from animal-derived components and assists consistent performance during vaccine production. Major players are focusing on development of serum-free formulations.

Single-use bioreactors and technologies - Single-use technologies are helping achieve flexible, consistent and scalable production compared to conventional stainless-steel bioreactors. This trend is positively impacting the viral vaccine cell culture media market.

Market Opportunities

Rising viral vaccine production in developing economies due to increasing disease burden is creating opportunities for viral vaccine cell culture media manufacturers to expand in emerging markets. Adoption of continuous manufacturing technologies using perfusion platforms can further improve productivity and efficiency of viral vaccine production. This presents lucrative opportunities for media manufacturers.

Impact Of COVID-19 On Viral Vaccine Cell Culture Media Market Growth

The outbreak of COVID-19 pandemic has severely impacted the growth of viral vaccine cell culture media market globally. The increased demand for vaccine development caused disturbance in the supply chain and manufacturing process of cell culture media. The lockdowns imposed by governments across various countries led to temporary closure of production facilities and disrupted import-export activities. This affected the availability of raw materials and components required for manufacturing cell culture media. Furthermore, restrictions on travel and transportation made it difficult for companies to conduct clinical trials and testing of vaccines under development.

However, with gradual lifting of lockdowns and resumption of business operations, the market is expected to regain lost momentum in post-COVID times. There is surge in R&D funding from governments and private organizations towards development of vaccines against coronavirus. This has boosted the demand for cell culture media from biopharmaceutical companies. Various start-ups and established players have entered into strategic collaborations with research institutes working on COVID-19 vaccines. They are focusing on expanding their production capacities to meet the growing requirements. Moreover, shift towards single-use technologies and automated solutions is expected to enhance production efficiency. Advancements in cell culture protocols will further drive the market growth in coming years.

Geographically, North America holds the major share of viral vaccine cell culture media market in terms of value, led by substantial research funding and presence of leading biopharma companies. Asia Pacific is emerging as the fastest growing regional market, supported by increasing government initiatives, improving healthcare infrastructure and growth of biosimilars industry in China and India. Recently, several Chinese manufacturers have started offering antibody and cell-based therapeutics against coronavirus. This is likely to boost the uptake of viral cell culture media in Asia Pacific post pandemic.

Impact Of COVID-19 On Viral Vaccine Cell Culture Media Market Growth In India

The COVID-19 outbreak hit India during the initial months of 2020. The country went into a nationwide lockdown enforcing travel restrictions and closure of non-essential services. This impacted the biopharmaceutical industry and temporarily disrupted the supply of cell culture media. Local production was halted as workforce mobility was constrained. Import of critical raw materials from other countries also reduced due to global supply chain disarray.

As a result, several vaccine developers faced challenges in terms of insufficient stock of cell culture media for ongoing R&D activities. Their pre-clinical research and clinical trials got delayed. However, as the lockdown rules were relaxed phase-wise, the Indian government initiated measures to resume operations following strict safety norms. It provided regulatory clearances and financial incentives for ramping up indigenous manufacturing of vaccine components including cell culture media.

India currently holds around 8-10% share of global biologics production. Post pandemic, efforts are being directed towards building self-reliance in vaccine manufacturing. Local players are augmenting their production capacities of viral cell culture media in collaboration with research institutes. Additionally, foreign companies are also evaluating India as an alternative manufacturing hub due to lower costs and large talent pool availability. Thus, India is anticipated to be one of the fastest growing regional markets for viral vaccine cell culture media in coming years.

Get more insights on this topic:  https://www.trendingwebwire.com/viral-vaccine-cell-culture-media-market-set-to-grow-due-to-advancements-in-cell-culture-techniques/

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This Viral Vaccine Cell Culture Media Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Viral Vaccine Cell Culture Media Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Viral Vaccine Cell Culture Media Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Viral Vaccine Cell Culture Media Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Viral Vaccine Cell Culture Media Market vendors

FAQ’s

Q.1 What are the main factors influencing the Viral Vaccine Cell Culture Media Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Viral Vaccine Cell Culture Media Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Viral Vaccine Cell Culture Media Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[mitalipingale]

https://carbonfacesocial.org/blogs/86251/Diphtheria-Pertussis-and-Tetanus-DTP-Vaccine-Market-Analysis-Size-Share

The Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is expected to reach US$ 8.67 billion by 2031 at a CAGR of 5.30%.

[nihannx]

Global Varicella Vaccine Market 2024 Key Players, Analysis, Share, Trends And Forecast To 2034

The Varicella Vaccine market report offered by Reports Intellect is meant to serve as a helpful means to evaluate the market together with an exhaustive scrutiny and crystal-clear statistics linked to this market. The report consists of the drivers and restraints of the Varicella Vaccine Market accompanied by their impact on the demand over the forecast period. Additionally, the report includes the study of prospects available in the market on a global level.

With tables and figures helping evaluate the Global Varicella Vaccine market, this research offers key statistics on the state of the industry and is a beneficial source of guidance and direction for companies and entities interested in the market. This report comes along with an additional Excel data-sheet suite taking quantitative data from all numeric forecasts offered in the study.

Get Sample PDF Brochure @ https://www.reportsintellect.com/sample-request/2911434

Key players offered in the market: Merck GSK Shanghai Institute BCHT Changsheng Keygen Green Cross Biken

Additionally, it takes account of the prominent players of the Varicella Vaccine market with insights including market share, product specifications, key strategies, contact details, and company profiles. Similarly, the report involves the market computed CAGR of the market created on previous records regarding the market and existing market trends accompanied by future developments. It also divulges the future impact of enforcing regulations and policies on the expansion of the Varicella Vaccine Market.

Scope and Segmentation of the Varicella Vaccine Market

The estimates for all segments including type and application/end-user have been provided on a regional basis for the forecast period from 2024 to 2034. We have applied a mix of bottom-up and top-down methods for market estimation, analyzing the crucial regional markets, dynamics, and trends for numerous applications. Moreover, the fastest & slowest growing market segments are pointed out in the study to give out significant insights into each core element of the market.

Varicella Vaccine Market Type Coverage: - Injection Freeze-Dried Powder

Varicella Vaccine Market Application Coverage: - Kids Injection Adults Injection

Regional Analysis:

North America Country (United States, Canada) South America Asia Country (China, Japan, India, Korea) Europe Country (Germany, UK, France, Italy) Other Countries (Middle East, Africa, GCC)

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/2911434

The comprehensive report provides:

Complete assessment of all opportunities and threats in the global market.

Varicella Vaccine Market recent advancements and major events.

A thorough study of business policies for the growth of the Varicella Vaccine Market leading players.

Concluding study about the growth plot of Varicella Vaccine Market for upcoming years.

Detailed understanding of Varicella Vaccine Market particular drivers, restraints, and major micro markets.

Favorable impression inside vital technological and market latest trends hitting the Varicella Vaccine Market.

Reasons to Purchase Varicella Vaccine Market Research Report

Develop a competitive approach based on the competitive landscape

Build business strategy by identifying the high growth and attractive Varicella Vaccine market classifications

Identify potential business partners, gaining targets and business buyers

Design financial investment policies based on estimated high potential segments

Prepare management and tactical presentations using the Varicella Vaccine market data

Plan for new product promotion and portfolio in advance

Contact Us: sales@reportsintellect.com Phone No: + 1-706-996-2486 US Address: 225 Peachtree Street NE, Suite 400, Atlanta, GA 30303

[trendtrackershq]

How Ceva Santé Animale is Shaping the Future of the Animal Vaccines Market

Introduction

Ceva Santé Animale, a global leader in animal health, is making significant strides in the Animal Vaccines Market. Known for its innovative approaches and commitment to improving animal health, Ceva is at the forefront of developing advanced vaccines and shaping market trends. This article explores how Ceva Santé Animale is influencing the animal vaccines market through strategic initiatives, emerging innovations, and recent developments.

Download FREE Sample: https://www.nextmsc.com/animal-vaccines-market/request-sample

Company Overview

Ceva Santé Animale, headquartered in Libourne, France, is a major player in the global animal health industry. Founded in 1999, the company has grown rapidly and now operates in over 110 countries. Ceva’s portfolio includes vaccines, pharmaceuticals, and feed additives for both companion animals and livestock.

Strategic Initiatives

Expansion Through Strategic Acquisitions

Ceva has adopted a proactive acquisition strategy to enhance its capabilities and market reach. By acquiring established companies and emerging players in the animal health sector, Ceva strengthens its product portfolio and expands its geographical footprint.

Recent Acquisitions: Notable acquisitions include the purchase of the veterinary vaccine division of the Danish company, Boehringer Ingelheim, and the acquisition of the animal health business of the French company, Virbac. These acquisitions have bolstered Ceva’s vaccine offerings and provided access to new markets.

Strategic Goals: These acquisitions align with Ceva’s goal to broaden its range of vaccines and enhance its global presence. By integrating complementary technologies and expertise, Ceva positions itself as a leader in innovative animal health solutions.

Investment in Research and Development

Ceva places a strong emphasis on research and development (R&D) to drive innovation and address emerging health challenges. The company invests heavily in R&D to develop new vaccines, improve existing formulations, and explore novel therapeutic approaches.

Innovation Centers: Ceva has established dedicated R&D centers focused on vaccine development. These centers work on creating vaccines for a wide range of diseases, from common conditions to emerging threats.

Collaborative Research: The company collaborates with academic institutions, research organizations, and other industry players to advance vaccine technology and share knowledge. This collaborative approach accelerates the development of cutting-edge vaccines and ensures that Ceva remains at the forefront of innovation.

Emerging Innovations

Development of Next-Generation Vaccines

Ceva is actively involved in the development of next-generation vaccines that offer improved efficacy, safety, and convenience. These innovations aim to address both existing and emerging disease threats in companion animals and livestock.

Recombinant Vaccines: Ceva is advancing the use of recombinant vaccine technology, which involves genetically modifying microorganisms to produce antigens. This approach enhances the precision and effectiveness of vaccines, targeting specific pathogens with greater accuracy.

DNA and mRNA Vaccines: The company is exploring the potential of DNA and mRNA vaccine technologies, which offer rapid development and adaptability to new and evolving pathogens. These technologies are expected to revolutionize vaccine development by providing flexible and effective solutions.

Needle-Free Vaccination Solutions

To improve vaccine administration and reduce stress for animals, Ceva is investing in needle-free vaccination technologies. These solutions offer a more comfortable and efficient way to deliver vaccines, especially in large-scale animal populations.

Jet Injectors: Needle-free jet injectors are being developed to administer vaccines without needles. This technology uses high-pressure streams to penetrate the skin, providing a painless and quick vaccination process.

Oral Vaccines: Ceva is also working on oral vaccine formulations that can be administered through feed or water. Oral vaccines simplify the vaccination process, especially for livestock, and enhance compliance in mass vaccination programs.

Inquire before buying: https://www.nextmsc.com/animal-vaccines-market/inquire-before-buying

Recent Developments

Launch of New Vaccine Products

Ceva has recently introduced several new vaccine products to address critical health issues in animals. These vaccines reflect the company’s commitment to innovation and its response to evolving health challenges.

Vaccine for Canine Parvovirus: Ceva launched a new vaccine for canine parvovirus, a highly contagious and potentially fatal disease. This vaccine offers enhanced protection and has been well-received by veterinarians and pet owners.

Poultry Vaccines: The company has expanded its poultry vaccine portfolio to include new products targeting avian influenza and Newcastle disease. These vaccines are designed to improve flock health and support the poultry industry’s biosecurity efforts.

Global Expansion and Market Penetration

Ceva is focusing on expanding its market presence, particularly in emerging regions. The company is strengthening its distribution networks and building partnerships to increase access to its vaccines and other animal health products.

Market Expansion: Ceva is targeting growth in key emerging markets such as Asia-Pacific, Latin America, and Africa. By investing in local operations and partnering with regional distributors, the company is enhancing its market reach and addressing the specific needs of these regions.

Local Production: To support its global expansion, Ceva is establishing local production facilities and enhancing its supply chain capabilities. This approach ensures timely availability of vaccines and reduces logistical challenges in delivering products to diverse markets.

Conclusion

Ceva Santé Animale is making a substantial impact on the animal vaccines market through its strategic initiatives, emerging innovations, and recent developments. By focusing on acquisitions, investing in R&D, and advancing vaccine technologies, Ceva is leading the way in improving animal health and addressing critical disease threats.

As the company continues to drive innovation and expand its global presence, it will play a crucial role in shaping the future of the animal vaccines market. Stakeholders in the animal health industry should closely monitor Ceva’s developments, as the company’s advancements will likely influence market trends and set new standards for vaccine efficacy and safety.

[marketsndata]

[poonamcmi]

Influenza Vaccines Market Driven by High Prevalence of Influenza Globally

The influenza vaccines market overview comprises influenza vaccines marketed for both seasonal and pandemic influenza. Influenza vaccines effectively provide immunity against various influenza strains by activating the immune system to produce specific antibodies. It helps prevent the flu or makes symptoms milder if contracted.

The influenza vaccines market is estimated to be valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.

Key Takeaways Key players operating in the influenza vaccines market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc. The key opportunities in the influenza vaccines market include new product developments targeting specific age groups and strains, potential pandemic opportunities, increasing government support to promote vaccination programs, and growing healthcare Infrastructure across emerging economies. Globally, manufacturers are focused on expanding their production facilities and distribution networks across Asia Pacific, Latin America, Middle East, and Africa to tap the high growth opportunities in these regions. Market Drivers The high prevalence of influenza globally is the major driver for the Influenza Vaccines Market Demand  As per WHO, influenza causes severe illness in about 3-5 million cases annually. The availability of government funding for vaccination programs especially in developed countries promotes market growth. Furthermore, growing awareness regarding influenza vaccination benefits and initiatives to promote immunization rates support the influenza vaccines market expansion.

PEST Analysis Political: Government Influenza Vaccines Market Size And Trends intervention and international funding on vaccine development through programs and regulations. Focus on preventive healthcare. Economic: Boost in healthcare expenditure. Opportunity for companies to invest in R&D. Vaccine demand expected to rise with awareness. Social: Growing public health concern regarding influenza outbreaks. Higher vaccine uptake due to health consciousness. Technological: Advancements in vaccine production technologies. Continuous innovations to address virus mutations. The United States represents the largest geographical market for influenza vaccines in terms of value, accounting for over 40% share in 2024. Factors such as high healthcare spending, large patient population and rising awareness levels contribute to its leading position. Asia Pacific region is expected to emerge as the fastest growing regional market for influenza vaccines between 2024-2031. Growing middle class population, increasing government support for vaccination programs and expansion of healthcare infrastructure are driving market growth in countries like China and India. Rising cases of influenza outbreaks also emphasize the need for preventive measures through vaccination in the Asia Pacific region.

Get More Insights On, Influenza Vaccines Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[xhealer]

The advent of messenger RNA (mRNA)-based vaccines has revolutionized the landscape of modern medicine, especially in the realm of infectious diseases.

[industryforecastnews]

Shingles Vaccine Market Size To Reach USD 11.26 Billion By 2030

Shingles Vaccine Market Growth & Trends

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.34% during the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

Shingles Vaccine Market Report Highlights

By product, Shingrix held the largest share in 2023, owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles

Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines

Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region

North America dominated the market in 2023, due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients.

Shingles Vaccine Market Segmentation

Grand View Research has segmented the global shingles vaccine market based on product, type, end-use, and region:

Shingles Vaccine Product Outlook (Revenue, USD Million, 2018 - 2030)

Shingrix

Zostavax

SKYZoster

Shingles Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)

Recombinant Vaccine

Live Attenuated Vaccine

Shingles Vaccine End Use Outlook (Revenue, USD Million, 2018 - 2030)

Private Healthcare Settings

Government Healthcare Settings

Shingles Vaccine Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

Kuwait

UAE

List of Key Players of Shingles Vaccine Market

GlaxoSmithKline plc.

Merck & Co., Inc.

SK chemicals

Green Cross Corp

Geneone Life Science

Vaccitech

CanSinoBIO

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

[bishtmeenakshi]

Insights into Trends in the Evolving Vaccine Landscape

Observe trends in the dynamic vaccine landscape, exploring industry size, future outlook, and segmentation within the vaccine sector. Insights into the evolving vaccine market are paramount.

[deepak28]

H1N1 (Swine Flu) Vaccination Market : Trends and Future Growth Analysis by 2031

The "H1N1 (Swine Flu) Vaccination Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside political, economic, social, technological, environmental, and legal factors. Expert opinions and recent developments highlight the geographical distribution and forecast the market's trajectory, ensuring a robust foundation for strategic planning and investment.

What is the projected market size & growth rate of the H1N1 (Swine Flu) Vaccination Market?

Market Analysis and Size

The H1N1 flu, sometimes also known as swine flu, is a type of influenza A virus. It was often known as swine flu and was a new combination of influenza viruses that infect pigs, birds and humans. There have been severe cases of influenza in recent times. As per the World Health Organization (WHO), annually, around 3 to 5 million cases of severe illness and approximately 2,90,000 to 6,50,000 respiratory deaths are because of seasonal influenza. Also, increasing levels of respiratory ailments and immune deficient ailments due to the increasing elderly population has further caused huge growth opportunities for the H1N1 (swine flu) vaccination market.

Data Bridge Market Research analyses that the H1N1 (swine flu) vaccination market, which was USD 13.29 billion in 2022, would rise to USD 21.51 billion by 2030 and is expected to undergo a CAGR of 6.20% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Browse Detailed TOC, Tables and Figures with Charts which is spread across 350 Pages that provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector.

This research report is the result of an extensive primary and secondary research effort into the H1N1 (Swine Flu) Vaccination market. It provides a thorough overview of the market's current and future objectives, along with a competitive analysis of the industry, broken down by application, type and regional trends. It also provides a dashboard overview of the past and present performance of leading companies. A variety of methodologies and analyses are used in the research to ensure accurate and comprehensive information about the H1N1 (Swine Flu) Vaccination Market.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-h1n1-swine-flu-vaccination-market

Which are the driving factors of the H1N1 (Swine Flu) Vaccination market?

The driving factors of the H1N1 (Swine Flu) Vaccination market include technological advancements that enhance product efficiency and user experience, increasing consumer demand driven by changing lifestyle preferences, and favorable government regulations and policies that support market growth. Additionally, rising investment in research and development and the expanding application scope of H1N1 (Swine Flu) Vaccination across various industries further propel market expansion.

H1N1 (Swine Flu) Vaccination Market - Competitive and Segmentation Analysis:

Global H1N1 (Swine Flu) Vaccination Market, By Vaccine Type (Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid), Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others) and End User (Hospitals, Clinics, and Others) – Industry Trends and Forecast to 2031.

How do you determine the list of the key players included in the report?

With the aim of clearly revealing the competitive situation of the industry, we concretely analyze not only the leading enterprises that have a voice on a global scale, but also the regional small and medium-sized companies that play key roles and have plenty of potential growth.

Which are the top companies operating in the H1N1 (Swine Flu) Vaccination market?

Some of the major players operating in the H1N1 (swine flu) vaccination market are:

Sanofi (France)

Pfizer Inc. (U.S.)

GSK plc (U.K.)

Novartis AG (Switzerland)

Mylan N.V. (U.S.)

Baxter.(U.S.)

AstraZeneca (U.K.)

Johnson & Johnson Private Limited (U.S.)

Virbac (France)

Vetoquinol (France)

Zoetis (U.S.)

Novavax (U.S.).

Zydus Group (India).

Panacea Biotec (India).

SINOVAC (China).

Abbott (U.S.)

SEQIRUS (U.S.)

Cipla Inc (India)

Short Description About H1N1 (Swine Flu) Vaccination Market:

The Global H1N1 (Swine Flu) Vaccination market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

North America, especially The United States, will still play an important role which can not be ignored. Any changes from United States might affect the development trend of H1N1 (Swine Flu) Vaccination. The market in North America is expected to grow considerably during the forecast period. The high adoption of advanced technology and the presence of large players in this region are likely to create ample growth opportunities for the market.

Europe also play important roles in global market, with a magnificent growth in CAGR During the Forecast period 2024-2031.

H1N1 (Swine Flu) Vaccination Market size is projected to reach Multimillion USD by 2031, In comparison to 2024, at unexpected CAGR during 2024-2031.

Despite the presence of intense competition, due to the global recovery trend is clear, investors are still optimistic about this area, and it will still be more new investments entering the field in the future.

This report focuses on the H1N1 (Swine Flu) Vaccination in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the H1N1 (Swine Flu) Vaccination Report 2024

What are your main data sources?

Both Primary and Secondary data sources are being used while compiling the report. Primary sources include extensive interviews of key opinion leaders and industry experts (such as experienced front-line staff, directors, CEOs, and marketing executives), downstream distributors, as well as end-users. Secondary sources include the research of the annual and financial reports of the top companies, public files, new journals, etc. We also cooperate with some third-party databases.

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2024-2031) of the following regions are covered in Chapters

What are the key regions in the global H1N1 (Swine Flu) Vaccination market?

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

This H1N1 (Swine Flu) Vaccination Market Research/Analysis Report Contains Answers to your following Questions

What are the global trends in the H1N1 (Swine Flu) Vaccination market?

Would the market witness an increase or decline in the demand in the coming years?

What is the estimated demand for different types of products in H1N1 (Swine Flu) Vaccination?

What are the upcoming industry applications and trends for H1N1 (Swine Flu) Vaccination market?

What Are Projections of Global H1N1 (Swine Flu) Vaccination Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about Import and Export?

Where will the strategic developments take the industry in the mid to long-term?

What are the factors contributing to the final price of H1N1 (Swine Flu) Vaccination?

What are the raw materials used for H1N1 (Swine Flu) Vaccination manufacturing?

How big is the opportunity for the H1N1 (Swine Flu) Vaccination market?

How will the increasing adoption of H1N1 (Swine Flu) Vaccination for mining impact the growth rate of the overall market?

How much is the global H1N1 (Swine Flu) Vaccination market worth? What was the value of the market In 2020?

Who are the major players operating in the H1N1 (Swine Flu) Vaccination market? Which companies are the front runners?

Which are the recent industry trends that can be implemented to generate additional revenue streams?

What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for H1N1 (Swine Flu) Vaccination Industry?

Customization of the Report

Can I modify the scope of the report and customize it to suit my requirements? Yes. Customized requirements of multi-dimensional, deep-level and high-quality can help our customers precisely grasp market opportunities, effortlessly confront market challenges, properly formulate market strategies and act promptly, thus to win them sufficient time and space for market competition.

Inquire more and share questions if any before the purchase on this report at - https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-h1n1-swine-flu-vaccination-market

Detailed TOC of Global H1N1 (Swine Flu) Vaccination Market Insights and Forecast to 2031

Introduction

Market Segmentation

Executive Summary

Premium Insights

Market Overview

H1N1 (Swine Flu) Vaccination Market By Type

H1N1 (Swine Flu) Vaccination Market By Function

H1N1 (Swine Flu) Vaccination Market By Material

H1N1 (Swine Flu) Vaccination Market By End User

H1N1 (Swine Flu) Vaccination Market By Region

H1N1 (Swine Flu) Vaccination Market: Company Landscape

SWOT Analysis

Company Profiles

Continued...

Purchase this report – https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-h1n1-swine-flu-vaccination-market

Data Bridge Market Research:

Today's trends are a great way to predict future events!

Data Bridge Market Research is a market research and consulting company that stands out for its innovative and distinctive approach, as well as its unmatched resilience and integrated methods. We are dedicated to identifying the best market opportunities, and providing insightful information that will help your business thrive in the marketplace. Data Bridge offers tailored solutions to complex business challenges. This facilitates a smooth decision-making process. Data Bridge was founded in Pune in 2015. It is the product of deep wisdom and experience.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 975

Email:- corporatesales@databridgemarketresearch.com

Browse More Reports:

Global Precision Farming Software Market – Industry Trends and Forecast to 2030

Global Oligosaccharides in Infant Nutrition Market – Industry Trends and Forecast to 2029

Global H1N1 (Swine Flu) Vaccination Market – Industry Trends and Forecast to 2030

Global Airbag Inflator Market - Industry Trends and Forecast to 2028

Global Veterinary Anti-Infective Market – Industry Trends and Forecast to 2029

[colinwilson11]

The viral vaccine cell culture media market possesses significant growth opportunities with the increasing prevalence of viral diseases and growing adoption of cell culture-based vaccine production processes. Cell culture media provide nutrients to sustain cell growth and maintain viability outside their natural surroundings. It finds widespread application in the cultivation of cells required for viral vaccine manufacturing.